BiotechTube
Graftys

Graftys

Aix-en-Provence, France· Est.
graftys.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $23M

Overview

Graftys is a commercial-stage company focused on synthetic bone graft substitutes, serving the orthopedic and dental markets. Its core technology platform involves highly biocompatible and osteoconductive calcium phosphate cements that are injectable and set in situ. The company has successfully brought products to market in Europe and other regions, positioning itself in the growing global bone graft substitute market. Its strategy involves both direct commercialization and partnerships to expand its geographic and clinical reach.

OrthopedicsDentistryTrauma

Technology Platform

Proprietary injectable calcium phosphate cement (CPC) platform for synthetic bone grafts. The platform features formulations that are osteoconductive, resorbable, and harden in situ with low heat, suitable for minimally invasive surgery.

Funding History

2
Total raised:$23M
Series B$15M
Series A$8M

Opportunities

The growing global demand for minimally invasive surgical procedures creates a strong tailwind for injectable bone graft substitutes like Graftys's products.
Expansion into large, regulated markets such as the United States through FDA clearance represents a significant untapped growth opportunity.
Additionally, the aging population and rising incidence of bone-related disorders provide a expanding addressable patient base.

Risk Factors

Intense competition from large, established medical device companies with greater resources and broader sales networks poses a significant market penetration challenge.
The regulatory pathway, particularly for FDA approval, is costly, lengthy, and uncertain, with no guarantee of success.
The company's growth is also dependent on continued surgeon adoption and training, which requires sustained commercial investment.

Competitive Landscape

Graftys operates in the highly competitive synthetic bone graft substitute market, competing directly with other biomaterial companies like Biomatlante, Medtronic's DBX, and Stryker's HydroSet, as well as broader orthobiologics players. Key differentiators are product handling (injectability, setting time), clinical data, and price. The competitive landscape is characterized by continuous innovation and consolidation, with larger players often acquiring promising technologies.

More companies in Regenerative Medicine →More companies in France →